SOFTAD Substance Use Outcomes Following TAD

SOFTAD TAD 后的物质使用结果

• 批准号: 6796683
• 负责人: JOHN F CURRY
• 金额: $ 56.15万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6796683
• 关键词: adolescence (12-20); clinical research; cognitive behavior therapy; drug abuse prevention; family; fluoxetine; human subject; interview; longitudinal human study; major depression; outcomes research; patient oriented research; statistics /biometry; substance abuse epidemiology; substance abuse related disorder

DESCRIPTION (provided by applicant): Substance abuse is a major public health problem among adolescents in the United States, associated with serious negative outcomes including high-risk sexual behavior and the leading causes of adolescent death: accidents, homicide and suicide. Substance use disorders (SUD's) are one of the three most common forms of adolescent psychiatric disturbance. Prevention of such disorders is a public health priority. The National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH) recently released RFA: DA-03-007, calling for investigations into the impact of child psychopathology and childhood interventions on subsequent drug abuse. This project, Substance use Outcomes Following Treatment for Adolescent Depression (SOFTAD) is an extended follow-up of adolescents who have completed the NIMH Treatment for Adolescents with Depression Study (TADS). We developed and are coordinating TADS, a 12-site study comparing cognitive behavior therapy (CBT), fluoxetine (FLX), combined CBT and FLX acutely to one another and to placebo, and longitudinally to one another in 432 adolescents with Major Depressive Disorder (MDD). TADS is the first adolescent MDD treatment study to include measures of substance use and abuse. We propose to enhance the measurement of substance use outcomes and related family factors and to extend the follow-up period from TADS treatment to five years in order to address critical questions emphasized in RFA: DA-03-007. These include the impact of treating MDD (and of specific treatments) on subsequent substance use outcomes, the identification of moderators and mediators of successful outcome in the affective and substance use domains, and the longitudinal relationship between adolescent MDD and substance use or abuse in a clinical sample. Approximately 300 adolescents will be followed and assessed every six months. Self-report, parent-report and diagnostic interview measures will be collected. The major hypothesis, that successful treatment of MDD will reduce subsequent substance use problems, and additional questions, will be tested using chi-square, logistic regression, and structural equation modeling. SOFTAD will be coordinated by the Duke Clinical Research Institute (DCRI), the same organization coordinating TADS, thus realizing substantial efficiencies and cost savings.

描述（由申请人提供）：药物滥用是美国青少年的一个主要公共卫生问题，与严重的负面后果相关，包括高风险性行为和青少年死亡的主要原因：事故、他杀和自杀。物质使用障碍（SUD）是青少年精神障碍的三种最常见形式之一。预防此类疾病是公共卫生的首要任务。美国国家药物滥用研究所 (NIDA) 和国家心理健康研究所 (NIMH) 最近发布了 RFA：DA-03-007，呼吁调查儿童精神病理学和儿童干预措施对后续药物滥用的影响。该项目“青少年抑郁症治疗后的药物使用结果”(SOFTAD) 是对已完成 NIMH 青少年抑郁症治疗研究 (TADS) 的青少年的长期随访。我们开发并正在协调 TADS，这是一项 12 个中心的研究，在 432 名患有重度抑郁症 (MDD) 的青少年中，对认知行为疗法 (CBT)、氟西汀 (FLX)、CBT 和 FLX 联合疗法以及安慰剂进行急性比较，并进行纵向比较。 TADS 是第一项包含药物使用和滥用措施的青少年 MDD 治疗研究。我们建议加强对物质使用结果和相关家庭因素的衡量，并将 TADS 治疗的随访期延长至五年，以解决 RFA：DA-03-007 中强调的关键问题。其中包括治疗 MDD（和特定治疗）对后续物质使用结果的影响、情感和物质使用领域成功结果的调节因素和中介因素的识别，以及临床样本中青少年 MDD 与物质使用或滥用之间的纵向关系。每六个月将对大约 300 名青少年进行跟踪和评估。将收集自我报告、家长报告和诊断访谈措施。主要假设是，MDD 的成功治疗将减少后续的药物使用问题和其他问题，将使用卡方、逻辑回归和结构方程模型进行测试。 SOFTAD 将由杜克临床研究所 (DCRI) 进行协调，该机构也负责协调 TADS，从而实现显着的效率和成本节约。